Clinical trial
A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®
NCT00391027 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00391027 |
|---|---|
| Title | A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus® |
| Official title | A Six Month, Open-Label Outpatient, Randomized Parallel Group Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera®) On Glycemic Control Compared To Insulin Glargine (Lantus®) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Or More Oral Agents |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Insulin Glargine (Lantus®), Inhaled Human Insulin (Exubera®) |
| Enrollment | 261 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Oct 23, 2006 |
| Last update posted | Jul 23, 2015 |
| Countries | Belgium, Finland, France, Germany, Netherlands, Norway, Poland, Spain, Sweden, Switzerland |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: